Analysis of Dengue Virus Type 3 Isolate DENV3-5_S_162 Polyprotein-Based Vaccine Candidate: In Silico Study

Abstract

Dengue Hemorrhagic Fever (DHF) is a serious infectious disease that warrants close attention due to its potential to progress rapidly into a life-threatening condition. It is commonly found in endemic areas and is often responsible for outbreaks. Among the four known Dengue virus serotypes, serotype 3 is most frequently associated with severe infections and serious complications in affected patients. The purpose of this study was to design a candidate dengue virus vaccine targeting dengue virus type 3 isolate DENV3-5_S_162 based on polyprotein. The characteristics of the resulting peptides are determined by their antigenicity, allergenicity, toxicity, instability and immunogenicity. The method used in this study is bioinformatics by utilizing several websites, namely the National Center for Biotechnology Information (NCBI) database, IEDB analysis resource, VaxiJen v2.0, AllerTOP v.2.0, ToxinPred, Protparam and Swiss model. The results of the application analysis showed that there were 2 potential peptides for dengue virus type 3 vaccine candidates, namely the GDQHQVGNETQGVTAEITPQASI peptide and the VEPGKNPKNFQTMPGTFQTTTGEI peptide. The peptide meets and has been tested with various stages such as antigenicity, allergenicity, toxicity, instability index and immunogenicity tests. The prediction results can be used as a reference for making a peptide vaccine for dengue virus type 3 isolate DENV3-5_S_162 with added value in terms of disease specificity, purity, production capacity, and production cost efficiency.